TrialCurveCLL14 (5-year update): reconstructed Kaplan–Meier curves
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Commun. 2023 Apr 18;14:2147. doi: 10.1038/s41467-023-37648-w |
|---|---|
| DOI | 10.1038/s41467-023-37648-w |
| Registry | NCT02242942 |
| Phase | Phase 3 |
| Conditions | Lymphocytic Leukemia, Chronic |
| Interventions | Chlorambucil, Venetoclax, Obinutuzumab |
| Sponsor | Hoffmann-La Roche |
| Enrolment | 445 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival
From figure panel a · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Ven-Obi not reached; Clb-Obi 36.4 months. Survival at 18 months: Ven-Obi 91%; Clb-Obi 77%. Hazard ratio Ven-Obi vs Clb-Obi 0.35 (95% CI 0.27–0.47).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Ven-Obi | 216 | 79 | not reached |
| Clb-Obi | 216 | 147 | 36.4 |
- Ven-Obi vs Clb-Obi: reconstructed HR 0.35 (95% CI 0.27–0.47)
Landmark survival (reconstructed)
| Time | Ven-Obi | Clb-Obi |
|---|---|---|
| 6 mo | 96.7% | 95.7% |
| 12 mo | 94.7% | 92.3% |
| 18 mo | 91.3% | 76.8% |
| 24 mo | 88.3% | 64.8% |
| 36 mo | 82.2% | 50.8% |
| 48 mo | 74.7% | 36.1% |
| 60 mo | 62.7% | 26.8% |
Overall survival
From figure panel d · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Ven-Obi not reached; Clb-Obi not reached. Survival at 18 months: Ven-Obi 93%; Clb-Obi 95%. Hazard ratio Clb-Obi vs Ven-Obi 1.31 (95% CI 0.86–2.01).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Ven-Obi | 216 | 38 | not reached |
| Clb-Obi | 216 | 56 | not reached |
- Clb-Obi vs Ven-Obi: reconstructed HR 1.31 (95% CI 0.86–2.01)
Landmark survival (reconstructed)
| Time | Ven-Obi | Clb-Obi |
|---|---|---|
| 6 mo | 97.2% | 97.7% |
| 12 mo | 95.8% | 96.2% |
| 18 mo | 93.3% | 95.3% |
| 24 mo | 91.9% | 93.4% |
| 36 mo | 89.0% | 88.0% |
| 48 mo | 85.5% | 83.1% |
| 60 mo | 82.0% | 76.9% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/cll14-5-year-update-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/cll14-5-year-update-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Nat Commun. 2023 Apr 18;14:2147. doi: 10.1038/s41467-023-37648-w doi:10.1038/s41467-023-37648-w. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/cll14-5-year-update
Report a problem with these data
Related trials
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
- PROLONG (final analysis): Overall survival; PFS after next-line treatment (randomization to second progression or de
- ECHELON-2 (5-year update): Overall survival; Progression-free survival per investigator
- ENDURE/CML-IX: Molecular relapse-free survival (MRFS); Re-achievement of MMR (probability of a first MMR
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- AGILE (long-term follow-up): Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials